Nurix Therapeutics, Inc. Stock Research

Market Summary

USD8.97-0.06

Delayedas of 23 Mar 2023, 12:42 pm

-0.66%

NRIX Stock Price

NRIX RSI Chart

NRIX Valuation

Market Cap

429.3M

Price/Earnings (Trailing)

-2.38

Price/Sales (Trailing)

11.11

EV/EBITDA

-2.08

Price/Free Cashflow

-2.5

NRIX Price/Sales (Trailing)

NRIX Profitability

EBT Margin

-466.93%

Return on Equity

-59.39%

Return on Assets

-43.28%

Free Cashflow Yield

-40.08%

NRIX Fundamentals

NRIX Revenue

Revenue (TTM)

38.6M

Revenue Y/Y

-8.29%

Revenue Q/Q

-37.14%

NRIX Earnings

Earnings (TTM)

-180.4M

Earnings Y/Y

-23.91%

Earnings Q/Q

-2.21%

Price Action

52 Week Range

7.5219.91

(Low)(High)

Last 7 days

3.1%

Last 30 days

-15.3%

Last 90 days

-21.7%

Trailing 12 Months

-30.6%

NRIX Financial Health

Current Ratio

4.51

NRIX Investor Care

Shares Dilution (1Y)

5.62%

Diluted EPS (TTM)

-3.71

Peers (Alternatives to Nurix Therapeutics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AAPL	2.5T	387.5B	-0.56%	-0.91%	25.94	6.37	2.44%	-5.35%
MSFT	2.1T	204.1B	-1.92%	-6.89%	30.5	10.08	10.38%	-5.25%
GOOG	1.3T	282.8B	1.63%	-25.54%	21.65	4.59	9.78%	-21.12%
AMZN	1.0T	514.0B	-3.36%	-34.72%	-376.42	1.99	9.40%	-108.16%
MID-CAP
NYMT	3.6B	258.4M	203.99%	176.76%	-11.9	13.75	24.91%	-254.56%
JBLU	2.3B	9.2B	-18.97%	-49.38%	-6.41	0.25	51.67%	-98.90%
SMALL-CAP
PLAY	1.7B	1.7B	-22.36%	-14.62%	13.72	0.97	61.79%	371.82%
TLRY	1.6B	602.5M	-17.77%	-52.80%	-2.74	2.63	18.18%	-18.59%
BYND	1.1B	418.9M	5.51%	-56.16%	-2.93	2.57	-9.85%	-101.06%
CGC	991.7M	478.9M	-11.35%	-65.42%	-0.32	2.07	-31.50%	-634.70%
MFA	954.9M	482.4M	-16.25%	-37.64%	-4.12	1.98	33.15%	-170.42%
NKLA	897.6M	50.8M	-34.66%	-77.56%	-1.14	17.66	1229.98%	-13.59%
GPRO	788.4M	1.1B	-10.56%	-33.33%	27.33	0.72	-5.82%	-92.23%
INO	281.8M	10.3M	-24.84%	-63.38%	-1.01	27.46	478.23%	7.85%

Financials for Nurix Therapeutics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-1.6%	38,627,000	39,240,000	38,701,000	34,360,000	29,750,000
Operating Expenses	4.8%	222,494,000	212,370,000	194,110,000	170,468,000	147,636,000
S&GA Expenses	1.5%	37,997,000	37,448,000	36,043,000	33,900,000	31,202,000
R&D Expenses	5.5%	184,497,000	174,922,000	158,067,000	136,568,000	116,434,000
EBITDA	-5.0%	-175,011,000	-166,734,000	-150,793,000	-	-
EBITDA Margin	-6.6%	-4.53	-4.25	-3.90	-	-
Earnings Before Taxes	-5.3%	-180,360,000	-171,301,000	-154,550,000	-135,392,000	-117,063,000
EBT Margin	-7.0%	-4.67	-4.37	-3.99	-	-
Net Income	-5.3%	-180,360,000	-171,345,000	-154,471,000	-135,452,000	-117,194,000
Net Income Margin	-6.9%	-4.67	-4.37	-3.99	-	-
Free Cahsflow	-5.4%	-172,051,000	-163,304,000	-145,450,000	-	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-9.3%	417	459	394	438	477
Current Assets	-10.3%	318	355	307	280	311
Cash Equivalents	35.6%	64.00	48.00	42.00	79.00	81.00
Net PPE	4.0%	17.00	17.00	16.00	14.00	11.00
Liabilities	-3.2%	113	117	128	132	134
Current Liabilities	4.7%	71.00	68.00	73.00	66.00	66.00
Shareholder's Equity	-11.3%	304	343	267	306	342
Retained Earnings	-13.2%	-401	-354	-308	-263	-220
Additional Paid-In Capital	1.2%	709	701	579	571	564
Accumulated Depreciation	6.3%	17.00	16.00	15.00	-	-
Shares Outstanding	0.1%	47.00	47.00	45.00	45.00	45.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-4.6%	-159	-152	-136	-135	-84.36
Share Based Compensation	14.0%	28.00	25.00	22.00	19.00	16.00
Cashflow From Investing	142.3%	27.00	-64.33	-13.49	-65.83	-108
Cashflow From Financing	-0.5%	117	118	4.00	154	154

Risks for NRIX

What is the probability of a big loss on NRIX?

92.8%

Probability that Nurix Therapeutics stock will be more than 20% underwater in next one year

89.2%

Probability that Nurix Therapeutics stock will be more than 30% underwater in next one year.

70.5%

Probability that Nurix Therapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NRIX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Nurix Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for NRIX

Cumulative Returns on NRIX

Which funds bought or sold NRIX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	sold off	-100	-147,000	-	-%
2023-03-06	Rockefeller Capital Management L.P.	added	575	4,000	4,000	-%
2023-02-28	Voya Investment Management LLC	unchanged	-	-37,020	197,980	-%
2023-02-24	NATIXIS	new	-	82,581	82,581	-%
2023-02-15	LAZARD ASSET MANAGEMENT LLC	new	-	11,000	11,000	-%
2023-02-15	Jasper Ridge Partners, L.P.	unchanged	-	-196,093	1,050,910	0.06%
2023-02-15	Metropolitan Life Insurance Co/NY	unchanged	-	-5,321	29,679	-%
2023-02-15	PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO	added	12.01	-55,000	919,000	-%
2023-02-15	MetLife Investment Management, LLC	unchanged	-	-47,298	255,702	-%
2023-02-15	NOMURA HOLDINGS INC	added	19.52	17,000	3,118,000	0.01%

Latest Funds Activity

Are funds buying NRIX calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own NRIX

No. of Funds

Nurix Therapeutics News

Schedule 13G FIlings of Nurix Therapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 24, 2023	deep track capital, lp	5.75%	2,717,171	SC 13G
Feb 14, 2023	third rock ventures iii, l.p.	0%	0	SC 13G/A
Feb 14, 2023	deep track capital, lp	4.81%	2,266,569	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	6.9%	3,253,736	SC 13G/A
Feb 14, 2023	redmile group, llc	9.9%	4,899,772	SC 13G/A
Feb 14, 2023	baker bros. advisors lp	9.99%	4,801,954	SC 13G/A
Feb 08, 2023	wasatch advisors inc	-	0	SC 13G
Jan 25, 2023	blackrock inc.	8.8%	4,142,528	SC 13G/A
Jun 10, 2022	deep track capital, lp	5.19%	2,436,164	SC 13G
Feb 14, 2022	third rock ventures iii, l.p.	5.4%	2,422,549	SC 13G/A

NRIX Fair Value

Recent SEC filings of Nurix Therapeutics

View All Filings

Date Filed	Form Type	Document
Mar 13, 2023	8-K	Current Report
Feb 24, 2023	SC 13G	Major Ownership Report
Feb 15, 2023	4	Insider Trading
Feb 15, 2023	4	Insider Trading
Feb 15, 2023	4	Insider Trading
Feb 15, 2023	4	Insider Trading
Feb 15, 2023	4	Insider Trading
Feb 14, 2023	SC 13G/A	Major Ownership Report
Feb 14, 2023	SC 13G/A	Major Ownership Report
Feb 14, 2023	SC 13G/A	Major Ownership Report

Latest Insider Trading transactions for NRIX

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-01-30	Ring Christine	acquired	-	-	1,924	general counsel
2023-01-30	Ring Christine	sold	-9,989	11.7796	-848	general counsel
2023-01-30	van Houte Hans	sold	-10,884	11.7796	-924	chief financial officer
2023-01-30	van Houte Hans	acquired	-	-	2,886	chief financial officer
2023-01-30	Wolff Stefani	acquired	-	-	962	evp and coo
2023-01-30	Wolff Stefani	sold	-4,994	11.7796	-424	evp and coo
2023-01-30	Hansen Gwenn	acquired	-	-	3,207	chief scientific officer
2023-01-30	Hansen Gwenn	sold	-16,632	11.7796	-1,412	chief scientific officer
2022-10-31	Ring Christine	sold	-9,003	12.8805	-699	general counsel
2022-10-31	van Houte Hans	sold	-9,518	12.8805	-739	chief financial officer

About Nurix Therapeutics

Arthur T. Sands

www.nurixtx.com

240

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

NRIX Income Statement

2022-05-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	May 31, 2022	May 31, 2021	May 31, 2022	May 31, 2021
Income Statement [Abstract]
Collaboration revenue	$ 11,432,000	$ 7,091,000	$ 21,053,000	$ 12,102,000
Operating expenses:
Research and development	47,493,000	25,994,000	90,630,000	48,997,000
General and administrative	9,654,000	7,511,000	18,882,000	14,041,000
Total operating expenses	57,147,000	33,505,000	109,512,000	63,038,000
Loss from operations	(45,715,000)	(26,414,000)	(88,459,000)	(50,936,000)
Interest and other income, net	314,000	171,000	525,000	489,000
Loss before income taxes	(45,401,000)	(26,243,000)	(87,934,000)	(50,447,000)
Provision for income taxes	0	139,000	0	210,000
Net loss	$ (45,401,000)	$ (26,382,000)	$ (87,934,000)	$ (50,657,000)
Net loss per share, basic	$ (1.01)	$ (0.60)	$ (1.96)	$ (1.23)
Weighted-average number of shares outstanding, basic	44,898,409	43,804,066	44,797,235	41,318,281
Net loss per share, diluted	$ (1.01)	$ (0.60)	$ (1.96)	$ (1.23)
Weighted-average number of shares outstanding, diluted	44,898,409	43,804,066	44,797,235	41,318,281

NRIX Balance Sheet

2022-05-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	May 31, 2022	Nov. 30, 2021
Current assets:
Cash and cash equivalents	$ 41,533	$ 80,506
Short-term investments	255,746	215,214
Accounts receivable		6,000
Income tax receivable		204
Prepaid expenses and other current assets	9,510	9,194
Total current assets	306,789	311,118
Long-term investments	51,538	137,189
Operating lease right-of-use assets	15,418	14,005
Property and equipment, net	15,507	11,340
Restricted cash	901	286
Other assets	4,157	2,833
Total assets	394,310	476,771
Current liabilities:
Accounts payable	6,142	6,650
Accrued expenses and other current liabilities	19,734	14,549
Operating lease liabilities, current	5,470	3,847
Deferred revenue, current	41,319	41,212
Total current liabilities	72,665	66,258
Operating lease liabilities, net of current portion	9,043	9,189
Deferred revenue, net of current portion	45,863	59,022
Total liabilities	127,571	134,469
Commitments and contingencies (Note 6)
Stockholdersʼ equity:
Preferred stock, $0.001 par value— 10,000,000 shares authorized as of May 31, 2022 and November 30, 2021; no shares issued and outstanding as of May 31, 2022 and November 30, 2021
Common stock, $0.001 par value— 500,000,000 shares authorized as of May 31, 2022 and November 30, 2021; 45,040,068 and 44,664,371 shares issued and outstanding as of May 31, 2022 and November 30, 2021, respectively	45	45
Additional paid-in capital	578,605	563,757
Accumulated other comprehensive loss	(3,085)	(608)
Accumulated deficit	(308,826)	(220,892)
Total stockholdersʼ equity	266,739	342,302
Total liabilities and stockholdersʼ equity	$ 394,310	$ 476,771